IVERIC bio Competitors and Similar CompaniesClear all

IVERIC bio's competitors and similar companies include Cipla, Genentech and UCB.

	IVERIC bio IVERIC bio (formerly known as Ophthotech) is a biopharmaceutical company engaged in the discovery and development of treatment options for retinal diseases.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
Founding Date	Founding Date 2007	Founding Date 1935	Founding Date 1976	Founding Date 1928
Type	Type Subsidiary	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Parsippany, US HQ Cranbury, US New York, US	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more
Employees	Employees 891% decrease	Employees 27,764	Employees 18,077	Employees 9,052
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ₹195b (FY, 2026)	Gross profit N/A	Gross profit €7.2b (FY, 2025)
Net income	Net income ($185.2m) (FY, 2022)	Net income ₹38.7b (FY, 2026)	Net income N/A	Net income €1.6b (FY, 2025)